EU Targets Illumina's Completion Of Grail Deal Amid Probe
European enforcers have launched an investigation into DNA sequencing company Illumina's decision to complete its $8 billion reacquisition of cancer-testing outfit Grail despite an ongoing merger review by the bloc's competition...To view the full article, register now.
Already a subscriber? Click here to view full article